Inhibikase Therapeutics annual r&d spending
2020
2021
2022
2023
2024
2025
Inhibikase Therapeutics R&D Spending Growth & History (IKT)
Inhibikase Therapeutics's r&d spending was $29.8M for fiscal 2025.
View full Inhibikase Therapeutics company overviewInhibikase Therapeutics annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $29.8M | $12.6M | +73.11% |
| 2024 | 2024-12-31 | $17.2M | $3.6M | +26.38% |
| 2023 | 2023-12-31 | $13.6M | $1.6M | +13.16% |
| 2022 | 2022-12-31 | $12.0M | $675,881 | +5.95% |
| 2021 | 2021-12-31 | $11.4M | $10.5M | +1170.87% |
| 2020 | 2020-12-31 | $893,802 | — | — |
Inhibikase Therapeutics quarterly r&d spending
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $13.4M | $8.1M | +154.10% |
| Q1 2026 | 2026-03-31 | $10.8M | $325,571 | +3.10% |
| Q4 2025 | 2025-12-31 | $6.4M | −$834,663 | −11.60% |
| Q3 2025 | 2025-09-30 | $7.6M | $3.5M | +82.58% |
| Q2 2025 | 2025-06-30 | $5.3M | $2.2M | +71.37% |
| Q1 2025 | 2025-03-31 | $10.5M | $7.8M | +282.13% |
| Q4 2024 | 2024-12-31 | $7.2M | $4.2M | +139.55% |
| Q3 2024 | 2024-09-30 | $4.2M | $964,322 | +29.90% |
| Q2 2024 | 2024-06-30 | $3.1M | −$1.5M | −32.19% |
| Q1 2024 | 2024-03-31 | $2.8M | −$102,840 | −3.60% |
| Q4 2023 | 2023-12-31 | $3.0M | −$51,178 | −1.68% |
| Q3 2023 | 2023-09-30 | $3.2M | $243,898 | +8.18% |
| Q2 2023 | 2023-06-30 | $4.5M | $1.6M | +52.09% |
| Q1 2023 | 2023-03-31 | $2.9M | −$162,872 | −5.40% |
| Q4 2022 | 2022-12-31 | $3.1M | −$336,100 | −9.91% |
| Q3 2022 | 2022-09-30 | $3.0M | −$172,900 | −5.48% |
| Q2 2022 | 2022-06-30 | $3.0M | $599,750 | +25.17% |
| Q1 2022 | 2022-03-31 | $3.0M | $585,131 | +24.06% |
| Q4 2021 | 2021-12-31 | $3.4M | $3.2M | +1393.87% |
| Q3 2021 | 2021-09-30 | $3.2M | $3.0M | +2516.39% |
| Q2 2021 | 2021-06-30 | $2.4M | $2.1M | +805.27% |
| Q1 2021 | 2021-03-31 | $2.4M | $2.1M | +758.97% |
| Q4 2020 | 2020-12-31 | $226,944 | — | — |
| Q3 2020 | 2020-09-30 | $120,569 | — | — |
| Q2 2020 | 2020-06-30 | $263,175 | — | — |
| Q1 2020 | 2020-03-31 | $283,114 | — | — |
Inhibikase Therapeutics r&d spending trends
Over the last five fiscal years, Inhibikase Therapeutics's r&d spending increased from $893,802 to $29.8M, a change of $28.9M. The latest reported quarter, Q2 2026, shows $13.4M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Inhibikase Therapeutics source filings ↗